Andrew Symes, United KingdomRoyal Free London NHS Foundation Trust Immunology
Presenter Of 1 Presentation
PATIENT-REPORTED QUALITY OF LIFE (QOL) FOLLOWING EXPERIENCE OF MANUAL PUSH METHOD WITH SUBCUTANEOUS IMMUNOGLOBULIN (SCIG) ADMINISTRATION IN PATIENTS WITH PRIMARY OR SECONDARY IMMUNODEFICIENCY
Background and Aims
Subcutaneous immunoglobulin (SCIg) is common among patients with primary or secondary immunodeficiency (PID/SID) and can be infused via pump or manual push. Here, we describe patient-reported quality of life (QOL) in a PID/SID cohort following transition to manual push from intravenous immunoglobulin (IVIg), pump-infused SCIg or no treatment (newly diagnosed).
Patients with any degree of experience of manual push completed two questionnaires on QOL and side effects: a hospital developed questionnaire and the Short Form Health Survey (SF-36). Both questionnaires were completed anonymously, 0–9 months after starting manual push.
Of the patients who completed the QOL questionnaire (25/49), 7 were IgG-naïve and 18 were on IgG prior to manual push (12 transitioned from IVIg, 1 from pump-infused SCIg and 5 from both). The majority of those previously on IgG treatment preferred manual push (78%; 14/18), citing increased convenience and fewer side effects as reasons. Overall, patients reported that manual push: saved time (80%; 20/25); offered greater flexibility (80%; 20/25); and had a positive financial impact (72%; 18/25). Over half reported manual push made taking the correct dose easier (56%; 14/25) and they felt less fatigued (52%; 13/25). Most would recommend manual push over other forms of administration (67%; 16/24). For SF-36 completers (N=24), mental component summary and physical component summary scores were the same or better than the general population in 67% (16/24) and 29% (7/24), respectively.
Patient-reported QOL improved in most patients following transition to manual push, with the majority recommending manual push over other forms of administration.